Newsfeeds - Spark Newswire

3 minute read

Daily Biotech Pulse: GSK’s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion’s Schizophrenia Candidate

By Vandana Singh

Today, 3:54 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ABBV

1 minute read

Alnylam Pharmaceuticals: Q2 Earnings Insights

By Benzinga Insights

Today, 3:54 PM

Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q2 earnings results on Thursday, July 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

ALNY

1 minute read

Analyst Ratings

Expert Ratings for Alnylam Pharmaceuticals

By Benzinga Insights

Today, 3:54 PM

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

ALNY

1 minute read

Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine

By Vandana Singh

Today, 3:54 PM

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) added one more patent infringement lawsuit against Moderna Inc (NASDAQ:MRNA), claiming it violated a newly obtained patent. The…

ALNY

4 minute read

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

By Shanthi Rexaline

Today, 3:54 PM

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

ACER

1 minute read

Analyst Ratings

Where Alnylam Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 3:54 PM

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

ALNY

1 minute read

Guggenheim Downgrades Alnylam Pharmaceuticals to Neutral

By Benzinga Newsdesk

Today, 3:54 PM

Guggenheim analyst Debjit Chattopadhyay downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Buy to Neutral.

ALNY

1 minute read

Analyst Ratings

Analyst Ratings for Alnylam Pharmaceuticals

By Benzinga Insights

Today, 3:54 PM

Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

ALNY

8 minute read

FDA
News

Alnylam Announces Publication Of Preclinical Results Based On Novel Conjugate Technology That Facilitates Delivery Of Short Interfering RNA To The Central Nervous System And Other Extrahepatic Tissues

By Benzinga Newsdesk

Today, 3:54 PM

Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues - Conjugation

ALNY

1 minute read

Alnylam’s Lumasiran Shows Clinical Benefit In Rare Kidney Disease

By Vandana Singh

Today, 3:54 PM

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) announced new results from the six-month primary analysis of the ILLUMINATE-C Phase 3 open-label study of lumasiran…

ALNY